Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer

Cancer Causes and Control

Volumn 18, Issue 2, 2007, Pages 211-218

  Freeman, Vincent L ^a,b   Flanigan, Robert C ^b   Meydani, Mohsen ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

Biochemical recurrence; Body mass index; Diet and nutrition; Prognosis; Prostatic neoplasms

Indexed keywords

FATTY ACID; OLEIC ACID; POLYUNSATURATED FATTY ACID; PROSTATE SPECIFIC ANTIGEN; STEARIC ACID;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; BODY MASS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER TISSUE; CAPILLARY GAS CHROMATOGRAPHY; CHEMICAL ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; EARLY CANCER; ENERGY BALANCE; ETHNICITY; FATTY ACID ANALYSIS; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY;

AFRICAN AMERICANS; AGED; BODY MASS INDEX; COHORT STUDIES; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATTY ACIDS; HUMANS; ILLINOIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK;

EID: 33846785000     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-006-0095-6     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics. CA Cancer J Clin 56:106-130
2. Ries LAG, Eisner MP, Kosary CL et al (eds) SEER Cancer statistics review, 1975-2002, National Cancer Institute. Bethesda, MD http://seer.cancer.gov/csr/ 1975_2002/results_merged/sect_23_prostate.pdf, Table XXIIII-4. Based on November 2004 SEER data submission, posted to the SEER web site 2005. (Last accessed September 12, 2006)
3. National Comprehensive Cancer Network, Clinical Practice Guideline in Oncology: Prostate cancer. (v.2.2005, January 26, 2006). http://www.nccn.org/. (Last accessed September 12, 2006)
4. Freedland SJ, Presti JC, Amling CL et al (2003) Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 61:736-741
5. Ward JF, Moul JW (2005) Biochemical recurrence after definitive prostate cancer therapy. Part 1: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol 15:181-186
6. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771
7. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523
8. Tewari A, Issa M, El-Galley R et al (2001) Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol 5:163-169
9. Amling CL, Riffengurgh RH, Sun L et al (2004) Pathologic variables and recurrence rates as related to obesity in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22:439-445
10. Freeland SJ, Aronson WJ, Kane CJ et al (2004) Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Region Cancer Hospital Database Study Group. J Clin Oncol 22:446-453
11. Strom SS, Wang X, Pettaway CA et al (2005) Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11:6889-6894
12. Chan JM, Holik CN, Leitzmann MF et al (2006) Diet after diagnosis and risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 17:199-208
13. Calle EE, Kaaks R (2004) Overweight, obesity, and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591
14. Campbell JK, Canene-Adams K, Lindshield BL et al (2004) Tomato phytochemicals and prostate cancer risk. J Nutr 134(12 Suppl):3486S-3492S
15. Chung BH, Mitchell SH, Zhang JS (2001) Effects of docosahexanoic acid and eicosapentaenoic acid on androgenmedicated cell growth in LNCaP prostate cancer cells. Carcinogenesis 22:1201-1206
16. Freeman VL, Meydani M, Hur K, Flanigan RC (2004) Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate cancer. Cancer 101:2744-2754
17. Hunter D (1998) Biochemical indicators of dietary intake. In: Willett W (ed) Nutritional Epidemiology, 2nd edn. Oxford University Press, New York, NY pp 174-243
18. Gleason DF (1977) Histologic grading of and staging of prostatic carcinoma. In: Tannenbaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia pp 171-197
19. Fleming ID, Cooper JS, Henson DE (1998) AJCC cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia
20. Bova GS, Fox WM, Epstein IJ (1993) Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue, review of processing techniques. Mol Pathol 6:201-207
21. Caruso U, Fowler M, Erceg M, Romano C (1991) Determination of very long chain fatty acids in plasma by a simplified gas chromatographic-mass spectrometric procedure. J Chromatogr 562:147-152
22. Woodrum DL, French CM, Hill TM et al (1997) Analytical performance of the Tandem®-R free PSA immuno-assay measuring free prostate specific antigen. Clin Chem 43:1203-1208
23. Kalbfleisch JD, Prentice RL (1980) Statistical analysis of failure time data. Wiley, New York, NY
24. Therneau TM, Grambsch PM (2000) Modeling survival data. Extending the Cox Model. Springer, New York, NY
25. SAS [computer program] (2002-2003) Version 9.1. Cary, NC: SAS Institute, Inc
26. Hussain T, Gupta S, Mukhtar H (2003) Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191:125-135
27. Ghosh J, Myers CE. (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 95:13182-13187
28. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79:935-945
29. Collett GP, Betts AM, Johnson MI et al (2000) Peroxisome proliferator-activated receptor alpha is an androgenresponsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res 6:3241-3248
30. Eastwood M (2003) Principles of human nutrition, 2nd edn. Blackwell Science Ltd, Oxford, UK
31. Dobrzyn A, Ntambi JM (2004) The role of stearoyl-CoA desaturates in body weight regulation. Trends Cardiovasc Med 14:77-81
32. Ntambi JM Miyazaki M, Stoehr PH et al (2002) Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. PNAS 99:11482-11486
33. Okada T, Furuhashi N, Kuromori Y, Miyashita M, Iwata F, Harada K (2005) Plasma palmitoleic acid content and obesity in children. Am J Clin Nutr 82:747-750
34. Baillargeon J, Rose DP (2006) Obesity, adipokines, and prostate cancer (review). Int J Oncol 28:737-745
35. Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911-999